Nebius Group N.V. (NBIS)

The panel's take

Verdict: WAIT · Conviction: MEDIUM · Last price: USD 236.33 (as of 2026-07-01)

Nebius is the panel's cleanest "real business, wrong price, fresh crack in the thesis" call. The growth is genuine and enormous: Q1 revenue jumped 684% year-over-year to $399M, AI-cloud ARR reached $1.92B (+54% QoQ), and the company carries a $50B contracted backlog anchored by Microsoft ($17.4B through 2031) and Meta (up to $27B), with Nvidia holding a ~$2B strategic stake and priority GPU access. But the stock still trades at roughly 60-70x trailing sales (~20x guided 2026 revenue) — pricing near-flawless multi-year execution — while the underlying business is loss-making (the headline GAAP profit came from a one-time ~$780M non-cash revaluation gain; the adjusted net loss widened to ~$100M) and consumes capital by design: 2026 capex is guided to $20-25B against ~$3B of revenue, roughly seven times sales. Then, on July 1, the reason for the ~13% drop that brought it back to $236: Bloomberg reported that Meta — its largest customer — is building "Meta Compute" to resell its own excess GPU capacity, i.e. the anchor tenant turning into a competitor. Four of six frameworks are bearish, with fair-value estimates clustering from ~$110 to ~$250, mostly below the price; only the disruptive-innovation lens is a firm bull, and the momentum lens is riding it but trimming. With a legitimate AI-infrastructure story, no margin of safety, and a live customer-concentration threat that management hasn't yet answered, the synthesis is WAIT — reassess after clarity on Meta and the next quarter.

Key levels

Key resistance starts at ~$262 (a near-term shelf), then ~$285, up to the $300 all-time high ($299.86) that must be reclaimed to negate the blow-off read. Key support sits at ~$222 (the round-number shelf near recent lows), then ~$190-200 (the prior breakout-retest zone — the level that would question the uptrend if lost), with deeper structural support near ~$155 (roughly a 50% retracement of the parabolic advance). The analyst consensus target spans an extraordinarily wide USD 120 to 380, averaging near USD 237 — essentially the current price, meaning consensus has been overtaken by the selloff rather than re-rated for the Meta news; the panel's own fair values ($110-250) sit at and below that, and target cuts are likely as the Meta Compute overhang is digested.

What legendary investors think

We ran Nebius past a panel of six legendary investors' frameworks.

Where they agree — and where they clash

The question it comes down to: Is Nebius an early, Nvidia-backed leader in a multi-year AI-infrastructure build-out whose $50B backlog justifies owning the volatility — or a capital-consumptive GPU-reseller priced for perfection, with fair value well below the quote and its biggest customer now building the very product it buys?

The numbers

Metric	Value
Price / Market cap	USD 236.33 / ~61B
P/S (TTM / fwd FY26)	~60–70x / ~19–22x (vs CoreWeave ~7–8x)
Revenue (Q1 2026)	USD 399M (+684% YoY); AI-cloud ARR $1.92B (+54% QoQ)
Profitability	Adj. net loss ~-$100M; GAAP profit was a one-time ~$780M non-cash revaluation gain; AI-cloud adj. EBITDA margin ~45%
2026 capex (guided)	USD 20–25B (~7x revenue)
Contracted backlog	~USD 50B (Microsoft ~$17.4B to 2031; Meta up to $27B)
Balance sheet	Cash ~$1.7B (≈$9.3B incl. recent raises); FCF ~zero; ~254M shares (+~30% in 18 mo)

Figures as of Q1 2026 (reported mid-May 2026) / July 1, 2026; sourced from Nebius IR/SEC 6-K, Futurum, Motley Fool, Bloomberg, MacroTrends, StockAnalysis, TipRanks. Headline GAAP net income (~$621M) was driven almost entirely by a $780.6M non-cash equity-revaluation gain (the Nvidia/other holdings), not operations — the adjusted net loss ($100M) is the representative figure. FY2026 guidance: revenue $3.0-3.4B, ARR target $7-9B exiting 2026, ~40% adjusted EBITDA margin. The ~7x capex-to-revenue ratio and ongoing dilution are the swing variables; the July 1 "Meta Compute" report (largest customer building a competing resale business) is the live catalyst behind the selloff.

The bottom line

Nebius is the panel's sharpest test of a real business against a demanding price and a freshly opened risk. The bull case is legitimate and, on the top line, spectacular: 684% revenue growth, ARR compounding 54% a quarter, a ~$50B backlog anchored by Microsoft and Meta, Nvidia as both supplier and shareholder, and 4GW of contracted power — the picks-and-shovels profile the disruptive-innovation lens is happy to underwrite toward a multi-year $500-700 outcome. But five of six frameworks see the same problems the bull acknowledges: the business is loss-making once you strip out a one-time revaluation gain, it burns capital by design ($20-25B of 2026 capex against ~$3B of revenue, funded by debt, dilution, and customer prepayments), it trades at ~20x forward sales with fair-value estimates clustering from ~$110 to ~$250 — mostly below the price — and it just absorbed a genuine blow to its moat thesis, with its largest customer reportedly building the very service it sells. Insiders have sold 17 times with zero buys since January, and short interest sits near 24% of the float. What would tip the call bullish is clarity that Meta Compute is additive rather than substitutive, continued backlog growth, and capex financed without heavy dilution — most of which the next quarter and management's response will start to answer. What keeps it a wait is that, until then, buyers are paying a priced-for-perfection multiple for a capital-hungry, loss-making reseller whose biggest customer just became a competitor — a real story worth revisiting, at a price and with a clarity that don't yet exist.

The panel's take

Verdict: WAIT · Conviction: MEDIUM · Last price: USD 219.65 (as of 2026-07-11)

Nebius is the panel's purest high-beta AI-infrastructure debate — explosive, contract-backed growth on one side, extreme capital intensity and dilution on the other. The growth is not a story: Q1 2026 revenue grew 684% year-over-year to $399M, core AI-cloud ARR reached $1.92B (+671%), adjusted EBITDA flipped positive, and management guides to a $7-9B exit-ARR by year-end — all validated by real hyperscaler commitments (a ~$27B Meta deal, a ~$17.4B Microsoft agreement, and Nvidia backing). That is why the GARP and innovation lenses are bullish: if the ARR target holds, the forward multiple compresses fast. But three lenses are bearish, and their concern is the funding model behind the growth: a $20-25B 2026 capex program — roughly 6-7x this year's revenue — funded by $4.3B of fresh convertibles, prefunded warrants, and rising debt, against a business still posting an adjusted net loss. The forensic lens flags that Q1 operating cash flow was driven by upfront customer prepayments (financing wearing an operating costume), that GPU depreciation jumped over 300% as management extended useful life from 4 to 5 years, and that the whole build rests on two counterparties' continued goodwill. With normalized fair-value estimates ($130-160) below the price, the stock ~30% off its high on capex-glut fears, and Q2 earnings days away, the synthesis is WAIT.

Key levels

Key resistance starts at ~$240 (the prior consolidation high before the final push), then ~$260, up to the ~$300 all-time high. Key support sits right underfoot at ~$217 (a ~38% retracement of the $85-to-$299 advance and the round $220 level), then ~$193 (this week's low, ~50% retracement), with a deeper historical accumulation zone near ~$160 at the rising Supertrend line. The analyst consensus target spans a very wide USD 125 to 380 — averaging near USD 240, only modestly above the price — a dispersion that mirrors the panel's own split between the contract-backed bulls and the capital-intensity bears.

What legendary investors think

We ran Nebius past a panel of six legendary investors' frameworks.

Where they agree — and where they clash

The question it comes down to: Is Nebius the scarce, contract-backed picks-and-shovels layer of the AI buildout — or a capital-devouring GPU landlord whose growth is funded by dilution and two customers' goodwill, priced above its intrinsic value before the economics are proven?

The numbers

Metric	Value
Price / Market cap	USD 219.65 / ~55B
Valuation	Forward P/S ~15-17x; ~5-7x EV/ARR on the $7-9B ARR target (no meaningful P/E)
Q1 2026 revenue	USD 399M (+684% YoY); core AI-cloud ARR $1.92B (+671%)
FY2026 guide	Revenue $3.0-3.4B; exit ARR $7-9B; adjusted EBITDA margin ~40%
Profitability	Adjusted EBITDA +$129.5M; adjusted net loss ~-$100M (GAAP profit was a non-cash gain)
Capacity / contracts	>3.5GW contracted (4GW target); Meta ~$27B, Microsoft ~$17.4B; Nvidia backing
Balance sheet	Cash ~$9.3B; non-current debt ~$8.4B; 2026 capex $20-25B (raised)

Figures as of Q1 2026 (reported May 13, 2026) / July 11, 2026; sourced from Nebius IR/SEC 6-K, Motley Fool, Businesswire, StockTitan, DataCenterDynamics, MarketBeat, StockAnalysis. Q1 GAAP net income ($621M) was driven by a $781M non-cash equity-revaluation gain — the underlying business still posts an adjusted net loss. The $20-25B capex program (raised from $16-20B) is funded by convertibles, prefunded warrants, and debt, creating real dilution risk; GPU useful-life was extended from 4 to 5 years. Analyst consensus ($240 avg, range ~$125-380). Next print: ~July 28-29, 2026 (Q2 2026).

The bottom line

Nebius is the panel's highest-variance WAIT — a genuine hyper-growth AI-infrastructure story sitting on a funding model the value lenses can't underwrite yet. The bull case is real and contracted, not speculative: revenue grew 684%, ARR reached $1.92B on its way to a guided $7-9B, adjusted EBITDA turned positive, and roughly $40B of Microsoft and Meta commitments plus Nvidia's backing validate the demand well ahead of the build — which is why the growth and innovation lenses see the multiple compressing fast if execution holds. The bear case is equally concrete: a $20-25B capex year running 6-7x revenue is funded by convertibles, warrants, and rising debt; GPU depreciation is climbing even as management extended useful lives; the reported profit was a non-cash gain; and the whole build leans on two customers' conditional commitments — leaving normalized fair-value estimates around $130-160, below the price. What would tip the call bullish is proof the economics work at scale — a Q2 print showing ARR tracking the $7-9B target with real, non-prepaid cash generation and capex discipline, plus a reclaim of the $260-280 zone on volume. What keeps it a wait is that, ~30% off its high and above the panel's intrinsic-value range, Nebius is still asking investors to fund an unproven, dilution-heavy build on two customers' goodwill — the demand is visible, but the returns are not yet.

The panel's take

Verdict: WAIT · Conviction: MEDIUM · Last price: USD 177.71 (as of 2026-07-18)

What changed since 2026-07-11:

• Price: USD 219.65 → 177.71 (-19%) — a two-week decline that pulled the stock into the panel's own $130-160 normalized fair-value band, compressing forward P/S to 12-14x.
• Panel: 2 of 6 → 1 of 6 now Bullish — The GARP Operator (Bullish → Neutral) and The Intrinsic-Value Modeler (Bearish → Neutral) both moved off their prior stance toward "wait for the print" rather than resolving in either direction; the Disruptive-Innovation Seeker remains the lone Bullish holdout.
• Trigger: The Q2 2026 print, due July 28-29 — roughly ten days out — is the catalyst nearly every lens now names as the thing that resolves the debate.
• Verdict: WAIT (unchanged)

The business facts are unchanged since Q1: revenue growth of 684% year-over-year, a $1.92B core AI-cloud ARR run rate, and $40B+ of Meta and Microsoft commitments sit against a $20-25B 2026 capex program — roughly 6-7x this year's revenue — funded by debt and dilution, with Q1 operating cash flow flagged by the forensic lens as prepayment-driven rather than organic. With price now inside the panel's own fair-value band rather than clearly above or below it, and virtually every lens pointing to the same near-term catalyst, the synthesis holds at WAIT until the Q2 print settles whether the ARR trajectory and capex discipline are intact.

Key levels

Key resistance now begins at ~$193 (last week's support shelf, flipped to overhead supply after the breakdown), then ~$217 (the prior retracement level), up to ~$240 (the last swing high before the decline). Key support sits at ~$163 (the rising Supertrend line, described by the panel as offering "almost no cushion left"), then a deeper historical accumulation zone near ~$140 that overlaps the panel's own fair-value band, with ~$85 as the next structural level referenced should $140 give way. An updated analyst consensus target was not available this week.

What legendary investors think

We ran Nebius past a panel of six legendary investors' frameworks.

Where they agree — and where they clash

The question it comes down to: Has the 19% decline repriced Nebius into a genuine historical accumulation zone ahead of a capex-and-ARR-proving Q2 print — or is the market only beginning to reflect a business whose growth is funded by two customers' goodwill and a balance sheet stretched by debt and dilution?

The numbers

Metric	Value
Price / Market cap	USD 177.71 / ~44B (approximate, scaled from prior share count)
Valuation	Forward P/S ~12-14x; ~4-6x EV/ARR on the $7-9B ARR target (no meaningful P/E)
Q1 2026 revenue	USD 399M (+684% YoY); core AI-cloud ARR $1.92B (+671%)
FY2026 guide	Revenue $3.0-3.4B; exit ARR $7-9B; adjusted EBITDA margin ~40%
Profitability	Adjusted EBITDA +$129.5M; adjusted net loss ~-$100M (GAAP profit was a non-cash gain)
Capacity / contracts	>3.5GW contracted (4GW target); Meta + Microsoft commitments $40B+ combined; Nvidia backing
Balance sheet	Cash ~$9.3B; non-current debt ~$8.4B; 2026 capex $20-25B

Figures as of Q1 2026 (reported May 13, 2026) / July 18, 2026; sourced from Nebius IR/SEC 6-K and prior panel coverage. Q2 2026 has not yet been reported — next print expected ~July 28-29, 2026. Market cap is approximate, scaled from the prior week's implied share count against the current price; an updated analyst consensus target was not available this week. The $20-25B capex program remains funded by convertibles, prefunded warrants, and debt, creating ongoing dilution risk.

The bottom line

The specific test now is the Q2 print itself: does it show ARR tracking toward the $7-9B exit target with cash generation that isn't prepayment-driven, and capex holding near $20-25B rather than drifting higher? A confirming print would let the three lenses currently sitting on Neutral move toward Bullish; a miss on either the cash-quality or capex-discipline question would validate the Moat Compounder's and Forensic Skeptic's concerns and likely push price back below the $130-160 fair-value floor. On the tape, a close below $160-163 opens $140 and then $85 as the next structural levels; a reclaim of $193-217 on volume would read as confirmation the AI-capex trade is intact again.

The panel's take

Verdict: WAIT · Conviction: MEDIUM · Last price: USD 187.77 (as of 2026-07-25)

What changed since 2026-07-18:

• Price: USD 177.71 → 187.77 (+5.66%) — but that headline number hides a violent round trip: an intraweek spike to $224.50 (Nvidia stake disclosure, ~+26%), a single-session -15% reversal on Meta-competition news, and a close back near $188. The stock touched and held its $163-166 support band exactly once ($164.31 low, 2026-07-13) along the way.
• Panel: 1 of 6 → 2 of 6 now Bullish — The Macro Opportunist upgraded from Neutral to Bullish, reading the Nvidia-stake-driven reclaim of the $193-217 resistance shelf as a confirmed breakout; The Disruptive-Innovation Seeker stays the other Bullish holdout. The Moat Compounder and The Forensic Skeptic remain Bearish; The GARP Operator and The Intrinsic-Value Modeler hold Neutral, both explicitly declining to chase a pre-earnings pop.
• New catalysts: Nvidia disclosed a 9.3% passive stake (13G, July 20-21); Nebius closed a $775M GPU-asset-backed debt facility (SOFR+2.5%, 2030 maturity) that funds part of 2026 capex without further dilution; a new $1B+ multi-year compute deal with Reflection AI (through 2029) adds a third contracted customer; analyst targets now cluster USD 217-258 across 17-23 analysts (Street high $410, low $120) versus "n/a" last week.
• New risk: A report that Meta — source of $27B of the $40B+ combined backlog — is building its own AI-cloud/compute business, raising the possibility the panel's largest concentration risk becomes a direct competitor rather than just a customer. This, not profit-taking, is what's credited with the -15% single-day reversal.
• Verdict: WAIT (unchanged)

Two consecutive intraweek rejections at the same $217-230 zone, both closing back near $187-188, sit next to heavy two-sided volume that reads as active repositioning rather than clean accumulation or distribution — the tape itself hasn't decided anything. The business facts are genuinely more resolved than a week ago on financing (non-dilutive debt beats another dilutive raise) and counterparty validation (Nvidia's stake, a third contracted customer), but genuinely less resolved on customer concentration (Meta's competing-business report is new and unaddressed) and cash-flow quality (still untested since Q1's prepayment flag). With the Q2 print now two trading days out and the panel split 2-2-2 rather than converging, the synthesis holds at WAIT: this is a bigger, noisier stack of open questions than last week's, not a settled one.

Key levels

Resistance has actually tightened, not loosened: price spiked intraweek to $230.30 and $218.54 on separate weeks but closed back below ~$193 both times, so the panel is pulling R1's lower edge down from $190-196 to $187-193 given the repeated closes right at that line. R2 (~217) and R3 (~240) are unchanged and untested from above since the June-July correction. On the support side, $163-166 (the rising Supertrend line) has now been tested once directly — it held exactly at the $164.31 low — which validates the level but means the "minimal cushion" framing from last week is a little more literal than before. $140 (fair-value overlap) and $85 (structural low) remain untested and unchanged. An analyst consensus target is available for the first time this cycle, and it sits meaningfully above the current price — though the $120-410 spread across sources is itself a signal of how unresolved the debate is.

What legendary investors think

We ran Nebius past a panel of six legendary investors' frameworks.

Where they agree — and where they clash

The question it comes down to: Have the Nvidia stake and the non-dilutive debt facility genuinely de-risked Nebius's growth story enough to justify paying up into Tuesday's print — or is the market pricing in confidence it hasn't earned yet, with the same prepayment-driven cash-flow question from last week (and a brand-new Meta-competition overhang) still completely unanswered?

The numbers

Metric	Value
Price / Market cap	USD 187.77 / ~USD 47.7B (July 24, 2026 close)
Valuation	Forward P/S ~13-15x; ~4-6x EV/ARR on the $7-9B ARR target (no meaningful P/E)
Q1 2026 revenue	USD 399M (+684% YoY); core AI-cloud ARR $1.92B (+671%) — Q2 not yet reported
FY2026 guide	Revenue $3.0-3.4B; exit ARR $7-9B; adjusted EBITDA margin ~40%
Profitability	Adjusted EBITDA +$129.5M; adjusted net loss ~-$100M (GAAP profit was a non-cash gain)
Capacity / contracts	>3.5GW contracted (4GW target); Meta ($27B) + Microsoft commitments $40B+ combined; new $1B+ multi-year Reflection AI deal (through 2029); Nvidia 9.3% stake disclosed
Balance sheet	Cash ~$9.3B; non-current debt ~$8.4B plus new $775M GPU-asset-backed facility (SOFR+2.5%, 2030 maturity); 2026 capex $20-25B
Analyst consensus target	USD 217-258 (17-23 analysts; Street high $410 Northland, low $120)

Figures as of Q1 2026 (reported May 13, 2026) plus dated updates through July 25, 2026: Nvidia 13G filing (Investing.com/StockTitan, 2026-07-20/21), $775M debt facility (24/7 Wall St, 2026-07-17), Reflection AI deal (Timothy Sykes/StocksToTrade, 2026-07-21), analyst targets (Benzinga, MarketBeat, 2026-07-20). Q2 2026 has not yet been reported — next print expected July 28-29, 2026 (Catacal). Market cap is approximate. The $20-25B capex program remains funded partly by convertibles, prefunded warrants, and now the new secured debt facility, alongside ongoing dilution risk.

The bottom line

Nothing this week actually settled the debate — it added a genuine bear catalyst (Meta reportedly building competing AI-cloud capacity) on top of genuine bull catalysts (Nvidia's stake, non-dilutive debt, a third contracted customer), and the market's own violent round trip through $224.50 and back to $187.77 shows it hasn't decided either. What tips this bullish from here: a Q2 print showing organic (not prepayment-driven) operating cash flow, capex holding near the guided $20-25B, and management directly addressing the Meta-competition overhang — that would let the two Neutral lenses and possibly the two Bearish ones move toward the Macro Opportunist's and Disruptive-Innovation Seeker's side. What tips it bearish: a repeat of Q1's cash-quality pattern, capex drifting past $25B, or confirmation the Meta relationship is deteriorating — any of which would validate the Moat Compounder's and Forensic Skeptic's concerns and put the $163 support level back in play. On the tape, a close back below ~$187-193 on volume reopens $163 and then $140; a sustained close above $217 would be the first real technical confirmation that this week's move was more than a pre-earnings press-release rally.

The panel's take

Verdict: SELL · Conviction: MEDIUM · Last price: USD 190.41 (as of 2026-08-01) · Changed from WAIT

What changed since 2026-07-25:

• Price: 187.77 → 190.41 (+1.41%)
• Panel: 2 of 6 → 1 of 5 now Bullish — composition also changed: added none; removed The Moat Compounder
• Trigger: BUY trigger: Weekly close above $209 with expanding volume AND operating margin inflecting toward breakeven (positive operating cash flow within 12 months), coupled with insider buying that reverses the selling trend. SELL breakdown confirmed: Weekly close below $180.94 opens the measured move to $157 → $97 POC.
• Verdict: WAIT → SELL

Three weeks ago the panel held at WAIT — The Moat Compounder was still in the room, and the balance of voices saw enough ambiguity around the business model to stay neutral. Now, with The Moat Compounder removed and replaced by deeper forensic scrutiny, the BUSINESS-objection camp has consolidated a clear majority: the −70% operating margins, $140M+ insider selling, and Altman Z-score of 1.49 are no longer seen as early-stage growing pains but as affirmative evidence of a cash furnace trading at fantasy multiples. The verdict tipped from WAIT to SELL not because the price moved — it barely budged, +$2.64 — but because the panel's center of gravity shifted decisively toward those who question whether the business itself can survive without dilutive capital raises.

The panel splits between The Disruptive-Innovation Seeker's lone BUY (AI infrastructure S-curve thesis) and a dominant BUSINESS-objection camp — The Intrinsic-Value Modeler, The GARP Operator, The Forensic Skeptic, and the Fundamental Scout all identify structural flaws: −70% operating margins, −$3.15B FCF, negative interest coverage, Altman Z-score of 1.49 in distress, no durable moat, and $140M+ of coordinated insider selling near the ATH. This is not a WAIT scenario — the cautious voices aren't merely asking for a lower entry price; they're questioning whether the business itself can survive without dilutive capital raises. The BUSINESS-objection camp carries higher aggregate conviction (The Forensic Skeptic 75%, The Macro Opportunist 72%, The Intrinsic-Value Modeler 65%, The GARP Operator 65%) and deeper forensic reasoning than the speculative bull case. SELL tips over HOLD because the bearish arguments are specific and severe — not mere uncertainty, but affirmative evidence of a cash furnace trading at fantasy multiples.

Key levels

What legendary investors think

We ran Nebius Group N.V. past a panel of 5 legendary investors' frameworks.

Where they agree — and where they clash

The question it comes down to: Can NBIS convert its $46B contract pipeline and Nvidia-backed GPU advantage into positive operating cash flow before its $9.4B cash pile — already matched dollar-for-dollar by $9.6B in debt — is consumed by $6B in annual capex, or will dilution and/or a credit crunch force a re-rating before the S-curve ever materializes?

The numbers

Metric	Value
Price / Market cap	USD 190.41 / ~USD 43B
P/E (TTM / fwd)	58.87x–65.52x (source-dependent) / n/a
ROE	14.14%
Operating margin	−70.55%
Dividend yield	n/a
Debt / equity	1.32
Free cash flow	−USD 3.15B

Figures as of August 1, 2026; sourced from stockanalysis.com, kaplio.com, and finance.yahoo.com.

The bottom line

A weekly close below $180.94 opens the measured move to $157 and potentially the $97 volume POC — the level where the bulk of historical accumulation actually occurred. On the flip side, the condition that would force a rethink is a weekly close above $209 with expanding volume, paired with operating margin inflection toward breakeven in the next two quarterly reports, and — critically — a reversal of the insider selling trend, even a single open-market purchase by the CEO. The $9.4B cash balance against $6B annual capex gives roughly 18–24 months of runway before the capital structure comes under acute stress; watch the August earnings report for any change in capex guidance or new financing disclosures. If revenue growth decelerates below 100% while operating losses widen, the bear case accelerates dramatically.

The panel's take

Verdict: BALANCED · Conviction: MED · Last price: 187.97 · Changed from SELL

What changed since 2026-08-01:

• Price: 190.41 → 187.97 (-1.28%)
• Panel: 1 of 5 → 0 of 6 now Bullish — composition also changed: added The Asymmetric Bargainer, The Quality Rationalist; removed The Disruptive-Innovation Seeker
• Trigger: BUY trigger: Weekly close above $190.70 (monthly 38.2% fib) with bullish MACD histogram turn AND evidence of operating leverage — a quarter showing revenue growth outpacing capex or insider buying by the CEO. SELL trigger: Break below $152.87 (weekly 61.8% fib) closing the Stage 2 window, or revenue deceleration below 100% YoY that validates the bear case on moat and capital efficiency.
• Verdict: SELL → BALANCED

The prior panel delivered a SELL at $190.41, but that panel lacked the voices who see a genuine Stage 2 trend with strong macro tailwinds. The current panel adds those perspectives (the Macro Opportunist and the Forensic Skeptic both recognize a valid uptrend that needs confirmation, not abandonment), while also adding two of the most bearish frameworks in the Quality Rationalist and the Asymmetric Bargainer. The price barely moved (-1.3%), but the debate shifted from "this is overvalued" to "this is either a great setup waiting to confirm or a business too broken to own." That genuine split on the nature of the problem, not just the price, is what moves the verdict from SELL to BALANCED: neither camp can claim the edge until the chart or the financials break the deadlock.

The panel divides into two camps that disagree on the nature of the problem, not just the price. The Macro Opportunist, The Forensic Skeptic, The Intrinsic-Value Modeler, and the scouts see a real AI-infrastructure story with a Stage 2 trend: they'd buy at a better price or on confirmation. The Quality Rationalist, The GARP Operator, and The Asymmetric Bargainer argue the business itself is broken: no moat, negative FCF, and insider selling by the CEO/CIO/CTO totaling $29M+ in 90 days is a disqualifier regardless of price. This is a genuine BUY-vs-SELL split on business quality, not a simple BUY-vs-WAIT split on timing. With neither camp dominating, no clear edge exists, so the verdict lands at BALANCED until one side is proven right.

Key levels

What legendary investors think

We ran Nebius Group N.V. past a panel of 6 legendary investors' frameworks.

Where they agree — and where they clash

The question it comes down to: Is NBIS an AI-infrastructure compounder catching its breath before the next leg up, or is it a story stock whose own executives and short sellers are already signaling how this ends?

The bottom line

• Trigger to confirm the breakout: A weekly close above $190.70 with a bullish MACD histogram turn would signal the correction is over and the Stage 2 trend is resuming, flipping the Macro Opportunist and Forensic Skeptic to buyers.
• Risk to monitor: A weekly close below $152.87 (the 61.8% Fibonacci retracement) would close the Stage 2 window and likely trigger a cascade of technical selling toward the $97 volume-weighted POC.
• Next catalyst: The next quarterly earnings report; look for revenue growth outpacing capex growth as the first sign of operating leverage, or conversely, revenue deceleration below 100% YoY that validates the bear thesis on moat and capital efficiency.
• The signal that overrides everything: Any insider open-market purchase by the CEO would be the single most powerful reversal signal; it would address the Quality Rationalist's, GARP Operator's, and Asymmetric Bargainer's core objection in one stroke.